An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Daiichi Sankyo has entered into an exclusive licence agreement worth up to $300m with Alteogen to develop a subcutaneous ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

After chemotherapy failure, if the cancer is also resistant to endocrine therapy, patients face a double obstacle: few ...

The only other drugs used to treat HER2-positive NSCLC are AstraZeneca and Daiichi Sankyo's antibody-drug conjugate Enhertu (trastuzumab deruxtecan ... are driven by HER2 mutations.

You've just been diagnosed with HER2+ breast cancer ... drugs your doctor might use include ado-trastuzumab emtansine (Kadcyla), fam-trastuzumab deruxtecan (Enhertu), lapatinib, margetuximab ...

T-Duo is a third-generation HER2-targeted antibody-drug conjugate ... efficacy of T-Duo in patients previously treated with trastuzumab deruxtecan. This study was supported by Byondis B.V. Co ...

More information: Coen J. Lap et al, Response of Human Epidermal Growth Factor Receptor 2–Expressing Prostate Cancer to Trastuzumab Deruxtecan, Annals of Internal Medicine (2024). DOI: 10.7326 ...

HER2-mutation testing turnaround time varies, and interpreting results can be complex, requiring clear guidelines and expert input. Efficient integration necessitates collaboration, continuous ...

BAY 2927088, which combines inhibition of HER2 (including exon 20 insertions and point mutations ... Enhertu (trastuzumab deruxtecan), which is cleared for second-line use only and is delivered ...